3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
5
Myeloid
3
Sarcoma
1
Lymphoid
1
Dermatologic
1
CNS
1
Conditions
Melanoma
273
Carcinoma, Non-Small-Cell Lung
49
Carcinoma, Renal Cell
37
Uveal Melanoma
23
Skin Neoplasms
23
Neoplasm Metastasis
23
Colorectal Neoplasms
22
Carcinoma, Transitional Cell
20
Carcinoma, Merkel Cell
20
Squamous Cell Carcinoma of Head and Neck
19
Neoplasms
18
Lung Neoplasms
17
Carcinoma, Hepatocellular
16
Brain Neoplasms
16
Triple Negative Breast Neoplasms
14
Uterine Cervical Neoplasms
13
Ovarian Neoplasms
13
Stomach Neoplasms
12
Urinary Bladder Neoplasms
10
Small Cell Lung Carcinoma
10
Head and Neck Neoplasms
9
Lymphoma
8
Carcinoma, Basal Cell
8
Pancreatic Neoplasms
7
Esophageal Neoplasms
7
Breast Neoplasms
7
Kidney Neoplasms
6
Sarcoma
5
Prostatic Neoplasms
5
Hodgkin Disease
5
Interventions
fludarabine phosphate
23
Cyclophosphamide
23
Peripheral Blood Stem Cell Transplantation
22
Antilymphocyte Serum
18
Busulfan
16
Tacrolimus
15
Mycophenolic Acid
15
Cyclosporine
14
Methotrexate
11
Filgrastim
11
Whole-Body Irradiation
10
Methylprednisolone
9
Melphalan
9
Sirolimus
6
Radiotherapy
6
Psychiatric Rehabilitation
6
Etoposide
6
Cord Blood Stem Cell Transplantation
6
sargramostim
4
Flow Cytometry
4
Early Intervention, Educational
4
Polymerase Chain Reaction
3
Epoetin Alfa
3
Darbepoetin alfa
3
Thiotepa
2
Therapeutics
2
Rituximab
2
Ondansetron
2
Moxifloxacin
2
Morphine
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Leukemia
×
Nivolumab
×
Dermatologic
×
Clear all
NCT04730349
2023-03-24
PIVOT IO 020
Bristol-Myers Squibb
Phase 1/2
Terminated
15 enrolled
14 charts